Targeted delivery of a short antimicrobial peptide against CD44-overexpressing tumor cells using hyaluronic acid-coated chitosan nanoparticles: An in vitro study
Source abstract
Abstract
Studies have shown that cationic antimicrobial peptides can be effective against tumor cells. Accordingly, in the current study, we evaluated the antitumor activity of a short cationic antimicrobial peptide (CM11) against CD44 overexpressing tumor cell lines, A549, SH-SY5Y, and PANC-1, by developing a targeted delivery system based on hyaluronic acid–coated chitosan nanoparticles (HA-CS NPs) in vitro. For preparation of delivery system, CM11-loaded chitosan nanoparticles were fabricated by the ionic gelation method, and in order to bond the carboxylic group of hyaluronic acid to amine groups of chitosan, EDC as the coupling agent was used. Following the optimization, the particle size and zeta potential of HA-CS NPs were measured which were 190 nm and + 28.9 mv with reasonable PDI of 0.280. In addition, encapsulation efficiency of peptide in nanoparticles was estimated approximately 60%. The in vitro release rate of the peptide from nanoparticles was also pH-dependent, which was higher in acidic pH (5–6) compared with the physiological pH (7.4). Based on MTT assay, the cytotoxicity of CM11-loaded HA-CS NPs against tumor cell lines was significantly higher compared with the CM11-loaded CS NPs and free peptide, while the cytotoxic effect of the free peptide on the normal cells was more than the nanoparticles containing the peptide. Flow cytometry–based apoptosis/necrosis assay also exhibited CM11-NP–induced apoptotic cell death. Our findings confirm the significant potential of CM11 peptide against tumor cells and its delivery system in order to target these cells.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Antimicrobial Peptides and Activities · RNA Interference and Gene Delivery · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (57)
Show source-provided references
1. Almalik A, Day PJ, Tirelli N (2013) HA-C oated chitosan nanoparticles for CD 44-mediated nucleic acid delivery. Macromol Biosci 13:1671–168010.1002/mabi.201300302 ↗
2. Amani J, Barjini KA, Moghaddam MM, Asadi A (2015) In vitro synergistic effect of the CM11 antimicrobial peptide in combination with common antibiotics against clinical isolates of six species of multidrug-resistant pathogenic bacteria. Protein Pep Lett 22:940–95110.2174/0929866522666150728115439 ↗
3. Antosiewicz JM, Shugar D (2016) UV–Vis spectroscopy of tyrosine side-groups in studies of protein structure. Part 2: selected applications. Biophys Rev 8:163–17710.1007/s12551-016-0197-7 ↗
4. Arranja AG, Pathak V, Lammers T, Shi Y (2017) Tumor-targeted nanomedicines for cancer theranostics. Pharmacol Res 115:87–9510.1016/j.phrs.2016.11.014 ↗
5. Arruebo M, Vilaboa N, Sáez-Gutierrez B, Lambea J, Tres A, Valladares M, González-Fernández Á (2011) Assessment of the evolution of cancer treatment therapies. Cancers 3:3279–333010.3390/cancers3033279 ↗
6. Brannon-Peppas L, Blanchette JO (2012) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 64:206–21210.1016/j.addr.2012.09.033 ↗
7. Calvo P, Remuñán-López C, Vila-Jato JL, Alonso M (1997) Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci 63:125–13210.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4 ↗
8. Cerchia L (2018) Aptamers: Promising Tools for Cancer Diagnosis and Therapy. Cancers (Basel):10, 13210.3390/cancers10050132 ↗
9. Cerchiara T et al (2015) Chitosan based micro-and nanoparticles for colon-targeted delivery of vancomycin prepared by alternative processing methods. Eur J Pharm Biopharm 92:112–11910.1016/j.ejpb.2015.03.004 ↗
10. Chidambaram M, Manavalan R, Kathiresan K (2011) Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci 14:67–7710.18433/J30C7D ↗
11. de Pinho Neves AL, Milioli CC, Müller L, Riella HG, Kuhnen NC, Stulzer HK (2014) Factorial design as tool in chitosan nanoparticles development by ionic gelation technique. Colloids and Surfaces A: Physicochemical and Engineering Aspects 445:34–3910.1016/j.colsurfa.2013.12.058 ↗
12. Diao L, Shen A, Yang Y, Tao J, Hu Y (2019) CD44-targeted hyaluronic acid–curcumin reverses chemotherapeutics resistance by inhibiting P-gp and anti-apoptotic pathways. RSC Adv 9:40873–4088210.1039/C9RA08202F ↗
13. Dosio F, Arpicco S, Stella B, Fattal E (2016) Hyaluronic acid for anticancer drug and nucleic acid delivery. Adv Drug Deliv Rev 97:204–23610.1016/j.addr.2015.11.011 ↗
14. Dragojevic S, Ryu JS, Raucher D (2015) Polymer-based prodrugs: improving tumor targeting and the solubility of small molecule drugs in cancer therapy. Molecules 20:21750–2176910.3390/molecules201219804 ↗
15. Farhadihosseinabadi B, Zarebkohan A, Eftekhary M, Heiat M, Moghaddam MM, Gholipourmalekabadi M (2019) Crosstalk between chitosan and cell signaling pathways. Cell Mol Life Sci 76:2697–271810.1007/s00018-019-03107-3 ↗
16. Felício MR, Silva ON, Gonçalves S, Santos NC, Franco OL (2017) Peptides with dual antimicrobial and anticancer activities. Front Chem 5:510.3389/fchem.2017.00005 ↗
17. Hermanson GT (2013) Bioconjugate techniques. Academic press, Cambridge
18. Honary S, Zahir F (2013) Effect of zeta potential on the properties of nano-drug delivery systems-a review (part 2). Trop J Pharm Res 12:265–273
19. Hoskin DW, Ramamoorthy A (2008) Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta 1778:357–37510.1016/j.bbamem.2007.11.008 ↗
20. Huang C-Y, Ju D-T, Chang C-F, Reddy PM, Velmurugan BK (2017) A review on the effects of current chemotherapy drugs and natural agents in treating non–small cell lung cancer. Biomedicine 7:2310.1051/bmdcn/2017070423 ↗
21. Jain A, Jain SK (2008) In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors. Eur J Pharm Sci 35:404–41610.1016/j.ejps.2008.08.008 ↗
22. Jain A, Jain SK (2016) Optimization of chitosan nanoparticles for colon tumors using experimental design methodology. Artif Cells Nanomed Biotechnol 44:1917–192610.3109/21691401.2015.1111236 ↗
23. Ji J et al (2014) Chemical modifications of chitosan and its applications. Polym-Plast Technol Eng 53:1494–150510.1080/03602559.2014.909486 ↗
24. Khalil DN, Smith EL, Brentjens RJ, Wolchok JD (2016) The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 13:27310.1038/nrclinonc.2016.25 ↗
25. Khan I, Saeed K, Khan I (2017) Nanoparticles: properties, applications and toxicities. Arabian J Chem 12(7):908–931. https://doi.org/10.1016/j.arabjc.2017.05.01110.1016/j.arabjc.2017.05.011 ↗
26. Kim K, Choi H, Choi ES, Park M-H, Ryu J-H (2019) Hyaluronic acid-coated nanomedicine for targeted cancer therapy. Pharmaceutics 11:30110.3390/pharmaceutics11070301 ↗
27. Kuroki M, Shirasu N (2014) Novel treatment strategies for cancer and their tumor-targeting approaches using antibodies against tumor-associated antigens. Anticancer Res 34:4481–4488
28. Mader JS, Hoskin DW (2006) Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs 15:933–94610.1517/13543784.15.8.933 ↗
29. Mattheolabakis G, Milane L, Singh A, Amiji MM (2015) Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J Drug Target 23:605–61810.3109/1061186X.2015.1052072 ↗
30. McGuire S (2016) World cancer report 2014. Geneva, Switzerland: World Health Organization, international agency for research on cancer, WHO press, 2015. Oxford University Press,10.3945/an.116.012211 ↗
31. Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR, Ghatak S (2011) Hyaluronan–CD44 interactions as potential targets for cancer therapy. FEBS J 278:1429–144310.1111/j.1742-4658.2011.08071.x ↗
32. Moghaddam MM, Barjini KA, Ramandi MF, Amani J (2014) Investigation of the antibacterial activity of a short cationic peptide against multidrug-resistant Klebsiella pneumoniae and Salmonella typhimurium strains and its cytotoxicity on eukaryotic cells. World J Microbiol Biotechnol 30:1533–154010.1007/s11274-013-1575-y ↗
33. Mohammadpour Dounighi N, Eskandari R, Avadi M, Zolfagharian H, Mir Mohammad Sadeghi A, Rezayat M (2012) Preparation and in vitro characterization of chitosan nanoparticles containing Mesobuthus eupeus scorpion venom as an antigen delivery system. J Venom Anim Toxins Incl Trop Dis 18:44–5210.1590/S1678-91992012000100006 ↗
34. Moravej H, Moravej Z, Yazdanparast M, Heiat M, Mirhosseini A, Moosazadeh Moghaddam M, Mirnejad R (2018) Antimicrobial peptides: features, action, and their resistance. Mechanisms in Bacteria. Microb Drug Resist. https://doi.org/10.1089/mdr.2017.039210.1089/mdr.2017.0392 ↗
35. Nakamura Y, Mochida A, Choyke PL, Kobayashi H (2016) Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? Bioconjug Chem 27:2225–223810.1021/acs.bioconjchem.6b00437 ↗
36. Nasti A, Zaki NM, De Leonardis P, Ungphaiboon S, Sansongsak P, Rimoli MG, Tirelli N (2009) Chitosan/TPP and chitosan/TPP-hyaluronic acid nanoparticles: systematic optimisation of the preparative process and preliminary biological evaluation. Pharm Res 26:1918–193010.1007/s11095-009-9908-0 ↗
37. O’Brien-Simpson NM, Hoffmann R, Chia C, Wade JD (2018) Antimicrobial and Anticancer Peptides. Front Chem 6:1310.3389/fchem.2018.00013 ↗
38. Oh EJ et al (2010) Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Control Release 141:2–1210.1016/j.jconrel.2009.09.010 ↗
39. Organization WH (2018) cancer fact sheet, february 2018.”
40. Pandey M et al (2018) Hyaluronic acid-modified betamethasone encapsulated polymeric nanoparticles: fabrication, characterisation, in vitro release kinetics, and dermal targeting. Drug Deliv Transl Res 9:1–14
41. Raji MA (2005) Management of chemotherapy-induced side-effects. Lancet Oncol 6:35710.1016/S1470-2045(05)70182-0 ↗
42. Rao NV et al (2016) Recent developments in hyaluronic acid-based nanomedicine for targeted cancer treatment. Expert Opin Drug Deliv 13:239–25210.1517/17425247.2016.1112374 ↗
43. Ravari NS et al (2016) Fabrication and biological evaluation of chitosan coated hyaluronic acid-docetaxel conjugate nanoparticles in CD44+ cancer cells DARU. J Pharm Sci 24:21
44. Rosenblum D, Joshi N, Tao W, Karp JM, Peer D (2018) Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun 9:141010.1038/s41467-018-03705-y ↗
45. Samal S, Dubruel P (2015) Cationic polymers in regenerative medicine. Royal Society of Chemistry, Cambridge10.1039/9781782620105 ↗
46. Song S et al (2014) Multifunctional tumor-targeting nanocarriers based on hyaluronic acid-mediated and pH-sensitive properties for efficient delivery of docetaxel. Pharm Res 31:1032–104510.1007/s11095-013-1225-y ↗
47. Steichen SD, Caldorera-Moore M, Peppas NA (2013) A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci 48:416–42710.1016/j.ejps.2012.12.006 ↗
48. Sun H et al (2019) Therapeutic strategies targeting cancer stem cells and their microenvironment. Front Oncol 9:110410.3389/fonc.2019.01104 ↗
49. Taghipour-Sabzevar V, Sharifi T, Moghaddam MM (2019) Polymeric nanoparticles as carrier for targeted and controlled delivery of anticancer agents. Ther Deliv 10:527–55010.4155/tde-2019-0044 ↗
50. Tiyaboonchai W (2013) Chitosan nanoparticles: a promising system for drug delivery. วารสาร มหาวิทยาลัย นเรศวร: วิทยาศาสตร์ และ เทคโนโลยี 11:51-66
51. Tran TH et al (2014) Hyaluronic acid-coated solid lipid nanoparticles for targeted delivery of vorinostat to CD44 overexpressing cancer cells. Carbohydr Polym 114:407–41510.1016/j.carbpol.2014.08.026 ↗
52. Vignesh S, Sivashanmugam A, Annapoorna M, Janarthanan R, Subramania I, Jayakumar R (2018) Injectable deferoxamine nanoparticles loaded chitosan-hyaluronic acid coacervate hydrogel for therapeutic angiogenesis. Colloids Surf B Biointerfaces 161:129–13810.1016/j.colsurfb.2017.10.033 ↗
53. Wais U, Jackson AW, He T, Zhang H (2016) Nanoformulation and encapsulation approaches for poorly water-soluble drug nanoparticles. Nanoscale 8:1746–176910.1039/C5NR07161E ↗
54. Wang JJ, Zeng ZW, Xiao RZ, Xie T, Zhou GL, Zhan XR, Wang SL (2011) Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomed 6:765
55. Wang H, Agarwal P, Zhao S, Xu RX, Yu J, Lu X, He X (2015) Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells. Biomaterials 72:74–8910.1016/j.biomaterials.2015.08.048 ↗
56. Xiao K et al (2011) The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 32:3435–344610.1016/j.biomaterials.2011.01.021 ↗
57. Yu M, Jambhrunkar S, Thorn P, Chen J, Gu W, Yu C (2013) Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells. Nanoscale 5:178–18310.1039/C2NR32145A ↗